SGLT2 inhibition with empagliflozin in patients with type 2 diabetes mellitus: Influences on left ventricular mass, function, and cardiac lipid content (EMPATROPHY)

Trial Profile

SGLT2 inhibition with empagliflozin in patients with type 2 diabetes mellitus: Influences on left ventricular mass, function, and cardiac lipid content (EMPATROPHY)

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 27 Jul 2017

At a glance

  • Drugs Empagliflozin (Primary) ; Glimepiride
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacodynamics
  • Acronyms EMPATROPHY
  • Most Recent Events

    • 20 Jul 2017 Status changed from not yet recruiting to recruiting.
    • 10 Jun 2017 Biomarkers information updated
    • 03 Nov 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top